All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
EquityEquity IPOs

Biotech fundraising boom continues with CureVac IPO

CureVac_Covid-19_Vaccine_ PA_575_375

Germany’s CureVac has gone public on the Nasdaq, joining the army of biotech companies that have tapped the equity capital markets for cash during the pandemic, despite growing concern of a brewing dot-com style bubble.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree